白雲山(00874.HK)子公司奇星藥業獲頒發《藥品生產許可證》
格隆匯 10 月 14日丨白雲山(00874.HK)公告,近日,廣州白雲山醫藥集團股份有限公司(“公司”)子公司廣州白雲山奇星藥業有限公司(“奇星藥業”)收到廣東省藥品監督管理局頒發的《藥品生產許可證》,同意奇星藥業作為上市許可持有人,廣州白雲山中一藥業有限公司、廣州粵華製藥有限公司、廣東澳珍藥業有限公司、廣東寶丹製藥有限公司及廣州白雲山醫藥集團股份有限公司白雲山製藥總廠作為受託生產方受託生產華佗再造丸、益婦止血丸、金丹丸等藥品。
奇星藥業於2017年6月取得華佗再造丸等75個品種“藥品上市許可持有人”藥品補充申請批件,成為華佗再造丸等75個品種的上市持有人;2019年12月,奇星藥業收到複方南板藍根顆粒等品種《藥品補充申請批件》,複方南板藍根顆粒等品種可進行委託生產。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.